Cancer Clinical Trial Eligibility: Applying FDA's 2026 Guidance to Protocol Design
How sponsors can reassess performance-status, laboratory, washout, and concomitant-medication exclusions without weakening drug-specific safety protections.
1. The Problem with "Perfect" Patients
For decades, oncology clinical trials have relied on highly restrictive inclusion and exclusion criteria. Sponsors designed these protocols to isolate the specific effect of an investigational drug and strictly protect patient safety. The ideal clinical trial candidate was essentially a "perfect" patient: relatively young, possessing perfect kidney and liver function, free of any prior malignancies, taking no complex concomitant medications, and exhibiting excellent physical mobility.
However, this practice systematically excludes a vast portion of the real-world cancer population. Cancer is fundamentally a disease of aging, and real patients frequently present with hypertension, mild organ dysfunction, diabetes, or a history of previous treatments. As a result, the "homogenous" cohorts in clinical trials often fail to represent the very patients who will actually receive the drug post-approval, leading to a profound lack of generalizability regarding the drug's true efficacy and safety profile.
2. What Changed in FDA's 2026 Eligibility Guidance Package?
FDA's July 2026 final guidances make this approach more concrete across three frequently restrictive domains. They apply to cancer clinical trials of investigational drugs and biological products regulated by CDER and CBER. They are nonbinding recommendations, not universal numerical eligibility rules or a requirement to enroll every patient subgroup.
- Performance status: The final guidance recommends including adults with ECOG PS 2 (or Karnofsky Performance Status [KPS] 60–70) unless a scientific or clinical rationale, supported by established safety considerations, justifies exclusion. It also discusses alternative approaches for broader low-PS populations, functional-status assessments, and implications for retention and sample size.
- Laboratory values: Laboratory thresholds should be tailored to the drug's mechanism, PK/PD, anticipated toxicities, and available clinical data. Sponsors should avoid carrying early-phase thresholds into later trials without reassessing whether they remain necessary. The guidance specifically addresses inter-laboratory variation, expected biological variation, and reassessment as development progresses; its recommendations focus mainly on later-phase trials.
- Washout periods and concomitant medications: Exclusions should have a disease- and drug-specific rationale. Relevant clinical or laboratory recovery parameters may be more appropriate than arbitrary time-based washouts when they address the actual safety concern. Concomitant medications should be excluded when clinically relevant interactions or overlapping toxicities affect safety, with dose or regimen adjustments considered where appropriate.
The underlying principle is not “broader is always better.” Eligibility should reflect the intended treatment population while preserving restrictions that are supported by the investigational product's pharmacology, toxicity profile, and the trial's objectives.
3. A Sponsor-Side Framework for Reviewing Eligibility Criteria
For each exclusion criterion, the protocol team should connect the threshold to a defined risk, supporting evidence, and a plan for monitoring or mitigation. The following questions translate the 2026 guidance into a practical review workflow.
| Domain | Protocol review questions | Evidence to document |
|---|---|---|
| Performance status | Could ECOG PS 2 be included? Is low PS driven by tumor burden, comorbidity, or another cause? Would a separate exploratory cohort be appropriate for patients with ECOG PS ≥2 beyond PS 2? | Prior-agent safety data, expected toxicity, baseline PS distribution, retention plan, stratification, and analysis approach. |
| Laboratory values | Does each threshold address a plausible drug-specific risk? Has it been reassessed using accumulated PK, safety, exposure-response, organ-impairment, or DDI data? | Mechanistic or clinical safety rationale, relevant reference ranges, inter-laboratory variability, repeat-testing rules, and phase-specific justification. |
| Washout | Is a fixed interval necessary, or can recovery of a relevant clinical/laboratory parameter address the risk? Could residual anti-tumor activity complicate endpoint attribution? | Prior-therapy PK/PD, half-life where relevant, delayed toxicity or anti-tumor effects, overlapping toxicity, and recovery criteria. |
| Concomitant medication | Is the restriction supported by a clinically meaningful DDI or overlapping toxicity? Could monitoring, dose adjustment, or an alternative medication mitigate the concern? | Investigational-drug DDI profile, transporter/enzyme effects, exposure-response, known class effects, and permitted alternatives. |
These questions should be answered criterion by criterion rather than by applying a blanket relaxation to the protocol. A restriction that is unnecessary for one drug may remain essential for another drug in the same disease setting.
4. Design Implications: Broader Eligibility Requires a Data Plan
Including patients with lower performance status may increase adverse-event rates, affect treatment exposure, and create additional retention demands. FDA recommends collecting baseline PS in all trials and considering stratification when the PS range is wide. For selected trials, sponsors may consider a prespecified low-PS cohort that is exploratory and separate from the primary efficacy analysis; the cohort definition, analysis strategy, and implications for labeling should be considered during protocol development and discussed with FDA when appropriate.
Laboratory criteria also need lifecycle management. A threshold used in a first-in-human study may have been a reasonable precaution when human safety data were limited. Once exposure, toxicity, organ-impairment, and DDI information accumulate, the same threshold should be reassessed rather than copied into Phase II or III by default. For washout rules, a clinically meaningful recovery condition can sometimes address safety more directly than a fixed number of days, while a time-based interval may still be justified when residual pharmacology or delayed anti-tumor effects matter.
Broader eligibility does not itself guarantee representative enrollment. Track screening failures and enrollment by the characteristics the protocol is intended to include, monitor safety and treatment delivery in those subgroups, and ensure the statistical analysis plan matches the population actually enrolled. If an expanded cohort is excluded from the primary efficacy analysis, that decision should be prespecified and transparently explained—not introduced after outcomes are known.
5. Eligibility Review Checklist
- Define the intended-use population for the investigational treatment and the trial's primary objective.
- For every exclusion, document the specific safety, PK/PD, interpretability, or operational concern it addresses.
- Use accumulated clinical and pharmacology data to reassess early-phase restrictions before later-phase trials.
- Specify monitoring, repeat-testing, recovery, dose-adjustment, or alternative-medication options where they can mitigate risk.
- Prespecify how broader eligibility affects stratification, sample size, retention support, subgroup analyses, and the primary analysis population.
- Review screening and enrollment data during the study to determine whether the criteria are achieving the intended population without compromising participant protection.
Toolkit Tip: Avoid treating a broadened-eligibility cohort and a historical restricted cohort as if they were randomized groups. Differences in disease burden, prior therapy, supportive care, calendar time, and assessment practices may confound comparisons. A Chi-Square Calculator can compare categorical counts under its assumptions, but a p-value alone does not resolve confounding or establish that an eligibility change caused a difference in response or toxicity.